Close

RedHill Biopharma (RDHL) Completes Enrollment in Ph-3 Study of RHB-105 for H. pylori Infection

April 27, 2015 7:16 AM EDT Send to a Friend
RedHill Biopharma Ltd. (Nasdaq: RDHL), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login